<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004376</url>
  </required_header>
  <id_info>
    <org_study_id>199/11979</org_study_id>
    <secondary_id>YALESM-7588</secondary_id>
    <nct_id>NCT00004376</nct_id>
  </id_info>
  <brief_title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the safety and efficacy of the alpha-2 adrenergic agonist guanfacine in children&#xD;
      and adolescents with Tourette syndrome or other chronic tic disorder, and attention deficit&#xD;
      hyperactivity disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by&#xD;
      pubertal status.&#xD;
&#xD;
      There is a 7- to 14-day washout with a placebo prior to treatment for all patients.&#xD;
&#xD;
      The first group receives oral guanfacine 3 times a day for 8 weeks. The dose is gradually&#xD;
      increased to minimize sedation; by day 14, most patients are stabilized and the dose is then&#xD;
      increased as clinically indicated and tolerated.&#xD;
&#xD;
      The second group receives a placebo 3 times a day for 8 weeks. Patients in either group may&#xD;
      be treated with guanfacine for an additional 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1994</start_date>
  <completion_date>June 2000</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>35</enrollment>
  <condition>Tourette Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>guanfacine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Tourette syndrome or other chronic tic disorder meeting Diagnostic and Statistical&#xD;
             Manual of Mental Disorders-IV (DSM-IV) criteria&#xD;
&#xD;
          -  DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD) Clinician's Global&#xD;
             Impression for ADHD greater than 4 Hyperactivity Index of Conners Parent or Teacher&#xD;
             Questionnaire standard score 65 or higher (1.5 standard deviation units)&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  At least 2 weeks since medication for tics, ADHD, or obsessive compulsive disorder (4&#xD;
             weeks since neuroleptics or fluoxetine)&#xD;
&#xD;
          -  No failure on prior guanfacine&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Hepatic: No liver failure&#xD;
&#xD;
          -  Renal: No renal failure&#xD;
&#xD;
          -  Cardiovascular: No hypertension No other heart disease&#xD;
&#xD;
          -  Pulmonary: No pulmonary disease&#xD;
&#xD;
          -  Other: No Intelligence Quotient below 80 No current DSM-IV diagnosis of the following:&#xD;
             Major depression Bipolar disorder Pervasive developmental disorder Psychotic disorder&#xD;
             No seizure disorder No other significant medical condition No pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Scahill</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <verification_date>March 2001</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Tourette syndrome</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

